Smoking
Also known as: Cigar smoking, Cigarette smoking, Pipe smoking, Tobacco smoking, Cigarettes
Methodology & AI Transparency ⓘ
Smoking Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are the health effects of smoking? There's no way around it; smoking is bad for your health.
- 2 Real-world patient consensus: Mapped to ADHD, Autism & Behavioral Health under ICD-10-CM F17.210 for Smoking clinical workups.
- 3 Typical cash cost range: Differential triage of Smoking (F17.210) utilizes baseline cardiovascular vitals in Smoking (F17.210: check).
- 4 Top reported side effects / signs: Follow-up benchmark in Smoking: maintaining Resting Blood Pressure in Smoking (F17.210: & Pulse (on) within < 125/80 mmHg; HR < 85 bpm (F17.210).
Ask our AI Specialists anything about Smoking
What Is Smoking?
What are the health effects of smoking? There's no way around it; smoking is bad for your health. It harms nearly every organ of the body, even some that you would not expect. Cigarette smoking causes many cancers and other health problems. It is also the cause of nearly one in five deaths in the United States. Some of the many health problems that smoking can cause include: Cancers. Smoking is the most common cause of lung and oral cancers. But it can also cause cancer in many other parts of your body, such as in your larynx (voice box), esophagus , throat , bladder , kidney , liver , stomach , pancreas , colon and rectum , and cervix .
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Smoking (F17.210) features norepinephrine alpha-2A) receptor in Smoking (F17.210: under-signaling across executive-control). Cross-referenced with NIH MeSH (Cigarette Smoking, Pipe Smoking), therapeutic stabilization in adhd & focus is verified against Serum Ferritin & in Smoking (F17.210: Iron Saturation).
Common Symptoms & Clinical Signs
- • Lung diseases . Smoking is the most common cause of COPD . It can also worsen asthma and raise your risk of pneumonia
- • Vision problems . Smoking can raise your risk of cataracts and cause macular degeneration (AMD)
- • Presentation of Smoking (F17.210): internal restlessness, impulsive in Smoking (F17.210: interrupting, or emotional)
- • Secondary Smoking clinical sign: compulsive reward-seeking behaviors in Smoking (F17.210: or difficulty moderating)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Smoking Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F17.210 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | ADHD, Autism & Behavioral Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Resting Blood Pressure in Smoking (F17.210: & Pulse (on) | < 125/80 mmHg; HR < 85 bpm (F17.210) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin & in Smoking (F17.210: Iron Saturation) | Ferritin 50 – 120 ng/mL (F17.210) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ASRS-v1.1 / Vanderbilt in Smoking (F17.210: Executive Score) | Functional symptom control (F17.210) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Smoking
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nicotine Quit Smoking Proven Patches, Nicotrol • RxCUI 1797886 | Cholinergic Nicotinic Agonist | 79% | $1.8990 | $ 85.41 /mo |
| Quit Smoking Proven Patches (Nicotine) Quit Smoking Proven Patches • RxCUI 198030-B84867013 | Cholinergic Nicotinic Agonist | 93% | $1.6017 | $ 123.82 /mo |
| Varenicline Tyrvaya, Chantix • RxCUI 636676 | Cholinergic Receptor Agonist | 93% | $0.2870 | $ 7.97 /mo |
| Rstrvbr Quit Smoking (Nicotine7mg Quit Smoking) Rstrvbr Quit Smoking • RxCUI 198031-B85248132 | Cholinergic Nicotinic Agonist | 82% | $2.1700 | $ 164.74 /mo |
| Wofanli Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) Wofanli Quit Smoking Nicotine Patches • RxCUI 198030-B85835004 | Cholinergic Nicotinic Agonist | 93% | $1.5089 | $ 117.14 /mo |
| Nicotine Stop Smoking Aid Step3 (Nicotine 7 Mg) Nicotine Stop Smoking Aid Step3 • RxCUI 198031 | Cholinergic Nicotinic Agonist | 83% | $1.6017 | $ 123.82 /mo |
| Nicduic Quit Smoking Nicotine Patches (Nicotine Transdermal Patches) Nicduic Quit Smoking Nicotine Patches • RxCUI 2707585 | Cholinergic Nicotinic Agonist | 94% | $1.5089 | $ 117.14 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Smoking)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among: What a 2,174-Participant Study Found All medications were generally safe in both MDD cohorts. The American journal of psychiatry • 2025-02-01 • Randomized Controlled Trial | N = 2,174 | 96/100 | PMID 39659160 ↗ |
| New Insights on Effects of varenicline, bupropion, nicotine patch, and placebo on smoking: What a 6,653-Participant Study Found Results suggest that for MDD smokers, inclusive of those with recurrent episode, varenicline plus counseling may be the best pharmacological option for the treatment of smoking given its greater efficacy effect size and... Depression and anxiety • 2022-05-15 • Randomized Controlled Trial | N = 6,653 | 96/100 | PMID 35535436 ↗ |
| New Insights on Cytisinicline for smoking cessation in individuals with self-reported COPD: a: What a 532-Participant Study Found Cytisinicline significantly increased quitting for smokers with and without COPD and was well tolerated. Thorax • 2026-01-15 • Phase III Randomized Trial | N = 532 | 93/100 | PMID 40962497 ↗ |
| New Insights on Efficacy of bupropion for relapse prevention in smokers with and without a past: What a 429-Participant Study Found Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression. Journal of general internal medicine • 2004-08-15 • Randomized Controlled Trial | N = 429 | 93/100 | PMID 15242467 ↗ |
| New Insights on Smoking behavior postmyocardial infarction among ENRICHD trial participants:: What a 1,233-Participant Study Found CBT for depression without more specific attention to smoking cessation may have little overall value as a strategy for helping post-MI patients refrain from smoking. Psychosomatic medicine • 2008-10-15 • Randomized Controlled Trial | N = 1,233 | 90/100 | PMID 18842753 ↗ |
Smoking Patient Community & “People Like Me” Threads
Filter Smoking community threads and patient logs by age, biological sex, dosage, and treatment duration.